Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $240 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 62.2%

Neg 0% Neu 62.2% Pos 0%

Cantor Fitzgerald analyst Carter Gould reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $240 price target.

Comments

No comments yet. Be the first!